Radiometals: Novel methods in production, radiochemistry and application

放射性同位素可以在核反应堆或粒子加速器中生产，由于反应堆的功率更高，而且紧凑的商业加速器（回旋加速器）相对稀缺，前者长期以来一直是全球生产模式的定义。然而，全球格局正在发生变化;基于回旋加速器的同位素生产现在更加普遍，而世界各地的反应堆计划在未来几年内下线。这种对我们同位素供应的威胁正在重新定义如何以及在哪里制造对科学和医学至关重要的同位素。加拿大早就认识到这一问题，并在回旋加速器技术方面投入了大量资金。这个国家现在拥有世界上最先进的粒子加速器基础设施之一，并拥有强大的放射性药物社区。 该提案将开发技术和化学，使加拿大和国际放射性药物研究界能够通过开发流行但难以生产和昂贵的金属放射性同位素来推动创新;同位素需要高功率基础设施来产生可用的数量。为此，该提案将利用TRIUMF的500 MeV回旋加速器辐照钍和铀靶，以产生两种放射性金属225 Ra和224 Ra，作为一系列子体（即225 Ac，212，213 Bi和212 Pb）的母同位素。这些同位素已经注意到作为治疗β、α、转换电子和俄歇发射体的应用。发射粒子的短路径长度和高线性能量传递（LET）在杀死细胞和癌组织方面非常有效。自玛丽居里时代以来，这种应用就得到了认可，但令人沮丧的是，世纪之后，研究仍然受到许多有前途的同位素的限制。 最初的研究将使用TRIUMF的同位素分离在线（ISOL）设施植入Ra同位素，随后的研究将分离和研究它们的配位化学。 拟议的研究工作将是TRIUMF和SFU之间更大的培训计划的一个组成部分，有助于建立新一代的科学家在加速器为基础的同位素生产和放射化学使用治疗放射性核素。学员将分离和纯化足够数量的所有同位素用于化学研究，这将为将来掺入蛋白质，肽和寡核苷酸等作为可能的治疗剂奠定基础。这项工作将包括目标准备、辐照目标操作、溶解、放射性核素提纯和放射化学研究方面的培训。所有学员都受到多学科研究环境的影响，从而培养出具有多方面技能的高素质人才，这些技能将物理，化学和生物学领域联系起来。

Radioisotopes can be produced either in nuclear reactors or particle accelerators, with the former having long-defined the global production paradigm due to the higher power of reactors and relative scarcity of compact, commercially available accelerators (cyclotrons). However, the global landscape is changing; cyclotron-based isotope production is now more prevalent, while reactors around the world are scheduled to go off-line within the next few years. This perceived threat to our isotope supply is re-defining how and where the isotopes most vital for use in science and medicine are made. Canada has long recognized this issue and has invested heavily in cyclotron technology. This country now boasts one of the most advanced particle accelerator infrastructures in the world, and with it, a strong radiopharmaceutical community. This proposal will develop technology and chemistry that will enable the Canadian and international radiopharmaceutical research communities to drive innovation by enabling the development of popular, but difficult to produce and expensive metallic radioisotopes; isotopes that require high-power infrastructure to generate usable quantities. To do so, this proposal will leverage TRIUMF's 500 MeV cyclotron to irradiate thorium and uranium targets to produce two radiometals, 225Ra and 224Ra, as parent isotopes for a series of daughters, namely 225Ac, 212,213Bi and 212Pb. These isotopes have noted applications as therapeutic beta, alpha, conversion electron and Auger emitters. The short path length and high linear energy transfer (LET) of the emitted particles are very effective in killing cells and cancerous tissues. Such applications have been recognized since the time of Marie Curie, but frustratingly, more than a century later, research continues to be limited by the poor availability of many promising isotopes. Initial studies will use TRIUMF's Isotope Separation Online (ISOL) facility to implant Ra isotopes, with later studies set to isolate and study their coordination chemistry. The proposed research effort will be an integral part of a larger training program between TRIUMF and SFU, helping to establish a new generation of scientists in accelerator-based isotope production and radiochemistry using therapeutic radionuclei. Trainees will isolate and purify sufficient quantities of all isotopes for chemistry studies, which will lay the groundwork for future incorporation into proteins, peptides, and oligonucleotides, etc. as possible therapeutic agents. This work will include training in target preparation, irradiated target manipulation, dissolution, radionuclide purification and radiochemistry studies. All trainees are subjected to a multi-disciplinary research environment, resulting in highly qualified individuals with a versatile skill set that bridges the fields of physics, chemistry and biology.